CuraTeQ Biologics s.r.o., announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorisation of Dazublys®, its trastuzumab biosimilar, for the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.